<DOC>
	<DOCNO>NCT02242240</DOCNO>
	<brief_summary>Study establish lung function effect add formoterol ( 12μg QD BID ) 2-week period pharmacodynamic steady state tiotropium ( 18μg QD )</brief_summary>
	<brief_title>Lung Function Changes Following Addition Formoterol Tiotropium Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>All patient must sign informed consent consistent international conference harmonization ( ICH ) good clinical practice ( GCP ) guideline prior participation trial , include medication washout restriction All patient must diagnosis chronic obstructive pulmonary disease must meet follow spirometric criterion : Patients must relatively stable* moderate severe airway obstruction FEV1 ≤ 60 % predict normal FEV1 ≤ 70 % FVC ( Visit 1 ) * Patients frequent exacerbation ( least three precede year ) could expect interfere patient 's ability participate trial exclude . The enrollment patient exacerbation within sixweek period prior plan study entry postpone least six week Predicted normal value calculate accord european community coal steel ( ECCS ) : Males : FEV1 predict ( L ) = 4.30 x Height ( metre ) 0.029 x Age ( year ) 2.49 Females : FEV1 predict ( L ) = 3.95 x Height ( metre ) 0.025 x Age ( year ) 2.60 Male female patient 40 year age old Patients must current exsmokers smoke history 10 packyears patient never smoke cigarette must exclude Patients must able perform technically acceptable pulmonary function test must able maintain record ( Patient Daily Record ) study period require protocol Patients must able inhale medication inhalation capsule delivery system ( HandiHaler® tiotropium placebo capsule Aerolizer® formoterol capsule ) meter dose inhaler Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Patients clinically relevant abnormal baseline hematology , blood chemistry , urinalysis abnormality defines disease list exclusion criterion All patient serum glutamate oxaloacetate transaminase ( SGOT ) &gt; 80 IU/L , serum glutamate pyruvate transaminase ( SGPT ) &gt; 80 IU/L , bilirubin &gt; 17 µmol/L creatinine &gt; 110 µmol/L ( male ) / 95 µmol/L ( female ) exclude regardless clinical condition . Repeat laboratory evaluation conduct patient Patients recent history ( i.e. , six month less ) myocardial infarction Patients cardiac arrhythmia require drug therapy hospitalize heart failure within past three year Patients know active tuberculosis Patients oxygen therapy Patients history cystic fibrosis , bronchiectasis , interstitial lung disease , pulmonary thromboembolic disease Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion 1 Patients respiratory infection six week prior Screening Visit ( Visit 1 ) baseline period Patients known hypersensitivity anticholinergic drug , beta adrenergic , lactose component inhalation capsule delivery system Patients history cancer within last three year . Patients treat basal cell carcinoma allow . Patients successfully treat cancer great five year prior entry allowed Patients know symptomatic prostatic hypertrophy bladder neck obstruction Patients know narrowangle glaucoma Patients use cromolyn sodium nedocromil sodium Patients use treated antihistamine ( H1 receptor antagonist ) Patients use treated theophylline Patients ßblocker therapy Patients use oral corticosteroid medication unstable dos ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day Pregnant nursing woman woman childbearing potential use medically approve mean contraception previous 3 month ( i.e . oral contraceptive , intrauterine device , diaphragm subdermal implant e.g. , Norplant® ) Patients history asthma , allergic rhinitis atopy total blood eosinophil count ≥ 600 mm3 . A repeat eosinophil count conduct patient Patients significant alcohol drug abuse within past two year Patients take investigational drug within one month six half life ( whichever great ) prior Screening Visit ( Visit 1 ) Patients currently pulmonary rehabilitation program complete program six week prior screen ( Visit 1 ) Patients currently participate another study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>